An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin is a research paper published in Journal of Clinical Investigation (2024). On theSindex it has a DataRank of 0.588. It has been cited 15 times, with 12 citing works in its 1-hop citation network.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.416
From this paper's citation signal
Citation Network Contribution
0.172
From 6 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 12 citers.
National Institute of Allergy and Infectious Diseases
Grant: R01AI155662
Nuvig Therapeutics
Grant: SRA
National Institutes of Health
Grant: 5R01AI155662-04
Harnessing the anti-inflammatory activity of extracellular sialylation of IgG.
National Institutes of Health
Grant: 5R01AI153441-04
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases
Fields of Study
Keywords